Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 5,902 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 3 Clear all
Completed Phase 1 Interventional Results available

Epigenetic Reprogramming in Relapse/Refractory AML

NCT03263936
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Decitabine, Vorinostat, Filgrastim (G-CSF), Fludarabine, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 25 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
28
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 23, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations

NCT04338711
View directory record Official record
Conditions
Healthy
Interventions
tofacitinib modified release (MR)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 23, 2026, 8:31 AM EDT
Completed Not applicable Interventional

A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery

NCT03115398
View directory record Official record
Conditions
Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastrointestinal Cancer, Cervical Cancer
Interventions
Pedometer-based Walking Program
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 8:31 AM EDT
Completed Phase 3 Interventional Results available

An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

NCT00945906
View directory record Official record
Conditions
Factor XIII Deficiency
Interventions
FXIII Concentrate (Human) (FXIII)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
25
States / cities
Dothan, Alabama • Oakland, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 23, 2026, 8:31 AM EDT
Recruiting Phase 3 Interventional

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

NCT06933472
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Interventions
AP301, AP301 Low Dose
Drug
Lead sponsor
Alebund Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Granada Hills, California • San Dimas, California • Lone Tree, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 23, 2026, 8:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Novel Determinants and Measures of Smokeless Tobacco Use: Study 2

NCT01067599
View directory record Official record
Conditions
Tobacco Use Disorder, Nicotine Dependence
Interventions
Low nicotine, Medium nicotine, High nicotine
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Minneapolis, Minnesota • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 23, 2026, 8:31 AM EDT
Terminated Phase 1 Interventional

An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)

NCT01742793
View directory record Official record
Conditions
Hodgkin's Lymphoma, Mature T-cell Lymphoma, Multiple Myeloma
Interventions
lenalidomide (Revlimid) and romidepsin (Istodax)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 23, 2026, 8:31 AM EDT
Recruiting Phase 1 Interventional

Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

NCT07220993
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
Interventions
CD7.CAR/28zeta T Cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2043
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 23, 2026, 8:31 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

NCT06922539
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Fenretinide
Drug
Lead sponsor
SciTech Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 8:31 AM EDT
Completed Phase 2 Interventional

Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)

NCT07016412
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg, Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
57
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 8:31 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Optimizing an Evidence-Based, Disseminable, Free Internet-Based Parenting Program

NCT05689736
View directory record Official record
Conditions
Parenting Practices
Interventions
Motivational Enhancement, Simplification, Gamification, Low Engagement Nudges, Essentials for Parenting Toddlers and Pre-schoolers (EFP)
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 99 Years
Enrollment
859 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 8:31 AM EDT
Not listed Not applicable Interventional

Cost Effectiveness and Clinical Utility of Cell Saver Use for Two to Three Level Lumbar Fusions

NCT01453309
View directory record Official record
Conditions
Low Back Pain Unresponsive to Non-surgical Care
Interventions
Cell Saver, No Cell Saver
Procedure
Lead sponsor
Norton Leatherman Spine Center
Other
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 23, 2026, 8:31 AM EDT
Completed Phase 3 Interventional Results available

Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)

NCT00406393
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
Interventions
Tacrolimus, Methotrexate, Sirolimus
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 60 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
23
States / cities
Duarte, California • La Jolla, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 23, 2026, 8:31 AM EDT
Completed Not applicable Interventional

Examining the Effects of a Telehealth Self-management Intervention in Multiple Sclerosis

NCT01572714
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Social Support Program, Physical Activity Program, Physical Activity Plus Fatigue Management Education Program
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 65 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 23, 2026, 8:31 AM EDT
Completed Not applicable Interventional

Evaluating a Mobile Phone Intervention

NCT04554706
View directory record Official record
Conditions
Depression, Rumination - Thoughts
Interventions
Mobile-phone delivered Treatment for Excessive Rumination
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 23, 2026, 8:31 AM EDT
Completed Not applicable Interventional Results available

Feasibility, Acceptability, and Barriers to Implementation of a Geriatrics Bundle in the ICU

NCT04652453
View directory record Official record
Conditions
Intensive Care Unit Syndrome
Interventions
Geriatrics Bundle
Other
Lead sponsor
Yale University
Other
Eligibility
65 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2024 · Synced Oct 23, 2026, 8:31 AM EDT
Terminated Phase 3 Interventional Results available

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

NCT03626545
View directory record Official record
Conditions
Non-Small-Cell Lung
Interventions
Canakinumab, Docetaxel, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 23, 2026, 8:31 AM EDT
Recruiting Phase 1 Interventional

Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

NCT07290244
View directory record Official record
Conditions
Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Interventions
ER-100 epigenetic therapy
Genetic
Lead sponsor
Life Biosciences Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Glendale, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 23, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

NCT03919409
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TS-161, TS-161 Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 23, 2026, 8:31 AM EDT
Active, not recruiting Phase 1 Interventional

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

NCT05614102
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY2965501, Pembrolizumab, Platinum-based Chemotherapy
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 8:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Oral Vitamin D Versus Narrow-Band UV-B Exposure on the Lipid Profile

NCT01688102
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Oral Vitamin D3, Ultraviolet Light
Dietary Supplement · Radiation
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 70 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 23, 2026, 8:31 AM EDT
Terminated Not applicable Interventional Results available

Clinical Trial to Evaluate Blister Graft Utilizing a Novel Harvesting Device for Treatment of Venous Leg Ulcers

NCT02148302
View directory record Official record
Conditions
Impaired Wound Healing, Venous Insufficiency of Leg, Diabetic Ulcers
Interventions
Harvesting Device (CelluTome©)
Device
Lead sponsor
SerenaGroup, Inc.
Network
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Boca Raton, Florida • Homestead, Florida • Largo, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 23, 2026, 8:31 AM EDT
Completed Phase 1 Interventional

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

NCT01230853
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Active Comparator: A, Placebo Comparator B, Active Comparator B, Placebo Comparator A
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Garden Grove, California • San Francisco, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 23, 2026, 8:31 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

NCT03740529
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Small Lymphocytic Lymphoma
Interventions
Pirtobrutinib, Venetoclax, Rituximab
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
31
States / cities
Scottsdale, Arizona • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 23, 2026, 8:31 AM EDT